Mr. Joyce has 25 years of public company CEO and Corporate Board experience. He is a recognized thought leader in the field of extracorporeal blood purification.

At Sigyn Therapeutics, Mr. Joyce is overseeing the development of CardioDialysis^TM to address cardiovascular disease, the leading cause of death worldwide. He has also established a pipeline of device candidates to improve cancer treatment outcomes. This includes ImmunePrep^TM to optimize the delivery of immunotherapeutic antibodies; ChemoPrep^TM to improve the delivery of chemotherapy; and ChemoPure^TM to reduce chemotherapy toxicity.

Previously, Mr. Joyce was the founder of Aethlon Medical, a therapeutic technology company he navigated from single-shareholder start-up to Nasdaq-traded company with a peak market value of ~$200 million during his tenure. At Aethlon, he oversaw the development of the Hemopurifier®, a first-in-class blood purification technology to target life-threatening viruses and cancer-promoting exosomes.  Under Mr. Joyce’s leadership, the Hemopurifier® became the first therapy to receive two FDA “Breakthrough Device” designations and was the first medical device cleared by FDA to treat a pandemic virus. As a result of these achievements, TIME magazine named the Hemopurifier® a “Top 25 Invention” and one of the “11 Most Remarkable Advances in Healthcare.”

Mr. Joyce has a diverse range of medical device industry experience. He has originated more than twenty preclinical or clinical device collaborations with leading government and non-government research organizations.

With support from Senator Joe Lieberman, he lobbied Capitol Hill and testified before Congress to expand the U.S. Government’s definition of a pandemic treatment countermeasure to be inclusive of medical devices.  This allowed for the Hemopurifier^® to be FDA cleared under Emergency-Use Authorization to treat Ebola virus and subsequently permitted blood purification therapies to become the first four therapies cleared by FDA to treat COVID-19.

Mr. Joyce participated in an FDA expedited-access pilot program with the Center for Devices and Radiological Health (CDRH) that would become a basis for FDA’s Breakthrough Device program.

Based on the advancement of the Hemopurifier® to treat HIV and Hepatitis-C in India, Mr. Joyce received the “Spirit of India Award” sponsored by the Bill & Melinda Gates Foundation and awarded each year to an American business leader who demonstrated a commitment to accelerate social and economic change in India.

Mr. Joyce also participated in a 5-year Department of Defense (DOD) program with the Defense Advanced Research Projects Agency (DARPA) to develop blood purification therapies to treat sepsis in wounded warfighters. 

On behalf of Aethlon Medical shareholders, Mr. Joyce founded Exosome Sciences, Inc. (ESI), to discover exosomal biomarkers.  Inspired by the death of a former teammate, Mr. Joyce established a collaboration with the Boston University CTE Center to evaluate circulating exosomes with tau protein cargos (exosomal tau) as a basis for a non-invasive blood test to diagnose and monitor chronic traumatic encephalopathy (CTE) and Alzheimer’s disease.   The Company participated in the first NIH funded clinical study of CTE, which revealed exosomal tau levels to be approximately 9x higher in former NFL players as compared to same age group control subjects. In a follow-on study, ESI reported exosomal tau levels to be similarly elevated in diagnosed Alzheimer's patients.  Researchers at Johns Hopkins would subsequently report exosomal tau to be the basis for a blood test that could diagnose Alzheimer's disease up to four years before first symptoms.

Upon graduating from the University of Maryland, Mr. Joyce was first employed as a member of the Denver Broncos Football Club of the National Football League.

Mr. Roberts is an inventor of life-saving therapeutic technologies, which includes a Percutaneous Adult Extracorporeal Membrane Oxygenation (ECMO) system that was licensed and subsequently sold to C.R. Bard. Mr. Roberts is also an inventor of the IMPACT System, which received CE Mark clearance in the European Union and was subsequently registered in 32 countries and deployed to treat cytokine storm associated conditions, including sepsis, acute respiratory distress syndrome (ARDS), acute liver failure, severe pneumonia, and H5N1 bird flu virus infection. The IMPACT system was comprised of multiple cartridges and designed to reduce the presence of inflammatory cytokines from human blood plasma. As a Clinical Perfusionist, Craig has conducted more than 4,000 extracorporeal procedures, including adult and pediatric cardiopulmonary bypass, cardiac assist devices, ECMO (artificial lung), vascular access catheter systems, and continuous renal replacement therapy.

Mr. Lynam has played key roles in developing, contracting and conducting over 190 clinical trials and will oversee clinical studies of Sigyn Therapy™ in the United States and abroad. Previously, Mr. Lynam was the Director of Scientific and Medical Affairs for Pharmatech Incorporated until its recent acquisition by Caris Life Sciences. While at Pharmatech, Mr. Lynam pioneered a high efficiency, patient centered clinical trials system, providing on-demand trial access to a network of more than 1,500 investigators.